An investigational oral targeted therapy, zipalertinib (CLN-081), demonstrated meaningful tumor responses and a manageable ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

The healthcare provisions include Medicaid work requirements and a broadening of the exemption to Medicare drug price negotiation ...

In an opinion article, investigators argue that gene therapies may not achieve their full potential if the innate inflammation in Duchenne muscular dystrophy is not effectively managed.

After a one-year follow-up, 10 of 12 patients given the islet cell therapy zimislecel no longer required insulin. Vertex ...

In a conversation with Managed Healthcare Executive, Michael Abrams, M.A., managing partner at Numerof & Associates, painted ...

Climate change and air pollution are growing threats to public health, and new research suggests they may also worsen atopic ...

While the impact of Medicaid changes on employer-sponsored insurance remains to be seen, competition between providers is a ...

Absent a federal committee’s recommendation, Duchenne muscular dystrophy advocates are trying to get states to adopt ...

Care gaps in women’s health are closing, thanks to increased cultural awareness of gendered healthcare disparities, according ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Employers, some lawmakers and others have criticized pharmacy benefit managers (PBMs), especially the "big three," for having ...